Search

Learn about a new multiple myeloma drug that can stop the disease after other treatments have failed.

… Thursday, August 24, 2023 There is good news about  multiple myeloma , a rare blood cancer that can be difficult to treat. This month, the FDA granted accelerated approval to a drug, elranatamab (Elrexfio™) for resistant forms of the disease.  “Widespread availability of elranatamab could help improve

Memorial Sloan Kettering is recognized worldwide for our expertise in diagnosing and treating central nervous system (CNS) lymphoma.

… Memorial Sloan Kettering is recognized worldwide for our expertise in diagnosing and treating central nervous system (CNS) lymphoma. Our skill and experience mean that we can offer you the best care possible. Select from the list below to learn more about our CNS lymphoma experts, including their education

MSK's Dr. Larry Norton, a national breast cancer expert, discusses how artificial intelligence is helping doctors.

… Monday, June 10, 2024 Artificial intelligence (AI) technology has been in the spotlight in recent months as AI chatbots and image generators have become widespread, leading to renewed conversations about the technology’s role in medicine. One of AI’s most immediate applications for patient care is to

Findings about proteins called molecular chaperones are shedding new light on possible approaches to cancer treatment.

… Thursday, November 10, 2016 Summary New research has shown that proteins called molecular chaperones work together in a communal relationship, suggesting new avenues for targeting their activity. Highlights Molecular chaperones help coordinate important activities inside cells.   Researchers are developing

Learn about our vast range of resources and support services available to the research community.

… A researcher Learn about the vast range of resources and support services available to our research community. Our group is responsible for protecting and licensing inventions developed by Memorial Sloan Kettering investigators, obtaining industrial funding for our laboratories, and negotiating and reviewing

… Full Title An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation Purpose Researchers

… Job Title Scientific Research Manager

Learn about metastatic prostate cancer treatments at MSK, including hormone therapy, chemotherapy, and immunotherapy delivered by prostate cancer experts.

… Metastatic prostate cancer is cancer that has spread to other parts of the body. Treatments for metastatic prostate cancer are called systemic therapies. These drugs move throughout your body to attack cancer cells wherever they are. Some systemic therapies can reduce the side effects of metastatic disease

Obtenga información sobre los tratamientos para el cáncer de próstata metastásico en MSK, incluida la terapia hormonal, la quimioterapia y la inmunoterapia administradas por expertos en cáncer de próstata.

… El cáncer de próstata metastásico es un cáncer que se ha diseminado a otras partes del cuerpo. Los tratamientos contra el cáncer de próstata metastásico se denominan terapias sistémicas. Estos fármacos circulan por todo el cuerpo para atacar las células cancerosas donde se encuentren. Algunas terapias

Eight leading cancer centers are coming together to share genomic sequencing data, in the hope of making faster progress in curing cancer.

… Thursday, January 5, 2017 Summary A collaboration among eight leading cancer centers, including MSK, is aiming to take advantage of genomic sequencing of patient tumors to advance the field of precision oncology. On January 5, the group is announcing the release of data on nearly 19,000 cancer patients